REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Conference Call Information
When: Wednesday, August 2nd, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI3fdbdc05783442f89d11db6b94e74a28
Webcast: https://edge.media-server.com/mmc/p/irz4npdq
The press release with the second quarter financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.
Please dial-in 15 minutes early to ensure a timely connection to the call.
Coherus Contact Information:
Marek Ciszewski, J.D.
SVP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.18 |
Daily Change: | 0.02 1.72 |
Daily Volume: | 577,125 |
Market Cap: | US$137.150M |
August 07, 2025 May 12, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load